ABOUT THE COMPANY
Oculis is an Iceland-founded global biopharmaceutical company that specializes in optic solutions. Founded in 2003 by Dr. Einar Stefánsson and Dr. Porsteinn Loftsson, these Icelandic professors developed the OPTIREACH solubilization technology which allows for eye drops to reach the back of the eye. This advancement was followed by years of continued innovation in the eye care sector, including drug development and technological breakthroughs. In March 2023, Oculis became a publicly traded company and dual listed on the Nasdaq in both the US and Iceland.
Today, Oculis’ headquarters are located in Switzerland, but its products have been used by people all over the world. Its mission of saving sight and improving eye care drives the patient-centered approach of the company and provides the foundation for the innovative work the company performs. Recently, Oculis has made strides in advancing its pipeline, including the successful completion of clinical trials for some of its products.
As Oculis looks to the future, it continues to focus on bringing forward solutions that could significantly improve the lives of patients with ocular diseases. Through expanding its current pipeline of treatments, pioneering non-invasive treatment options, advancing clinical trials, and pursuing strategic partnerships, the company constantly works towards innovation and improvement.
